Danaher (DHR) is in focus after subsidiary Masimo received FDA 510(k) clearance for an AI-enabled feature that detects opioid-induced respiratory depression in hospital patients via the Radius VSM wearable monitor.

Beyond today’s FDA news, Danaher’s recent share price momentum has picked up, with a 1-day share price return of 5.53% and 30-day share price return of 9.81%. However, the year-to-date share price return is still down 18.03%, and the 5-year total shareholder return is down 18.81%.

If this kind of healthcare AI progress interests you, it could be worth scanning other opportunities through the 38 healthcare AI stocks

With Danaher still down year to date despite recent gains and trading below some intrinsic and analyst value estimates, the key question is whether there is a bargain here or whether the market is already pricing in future growth.

Most Popular Narrative: 23.8% Undervalued

Danaher’s most followed narrative places fair value at $247.83 per share, above the last close at $188.87, framing today’s move as only part of a wider valuation gap.

The sustained advancement of precision medicine and personalized therapies, including new AI-assisted diagnostic solutions and launches in genomics (like support for in vivo CRISPR therapies), is expected to position Danaher's technology portfolio to capture higher-margin opportunities.

Want the full story behind that $247.83 figure? The narrative focuses on the relationship between revenue trends, margins and a premium earnings multiple.

Result: Fair Value of $247.83 (UNDERVALUED)

However, this Danaher narrative could be challenged if trade tensions and policy shifts in China continue to weigh on diagnostics demand, or if bioprocess funding remains subdued.

Next Steps

If the mixed sentiment around Danaher has you curious, this is a good moment to review the details and stress test the bullish points yourself, starting with the 3 key rewards

Looking for more investment ideas beyond Danaher?

Do not stop at Danaher. Use the Simply Wall Street Screener to quickly spot other stocks that match the kind of opportunities you are searching for today.

• Target resilient potential by checking out 69 resilient stocks with low risk scores, which may better align with a preference for steadier risk profiles.
• Hunt for possible mispriced opportunities through the 44 high quality undervalued stocks and see which stocks currently sit below their estimated fair value.
• Tap into income ideas using the 7 dividend fortresses if reliable, higher-yielding payouts are a key part of your approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.